Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer

• Published in: Radiation oncology (London, England) Vol. 7; no. 1; p. 114
• Main Authors: Shi, Liangrong, Wu, Changping, Wu, Jun, Zhou, Wenjie, Ji, Mei, Zhang, Hongyu, Zhao, Jiemin, Huang, Yuanquan, Pei, Honglei, Li, Zhong, Ju, Jingfang, Jiang, Jingting
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 24.07.2012; BioMed Central; BMC
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - pathology; Adenocarcinoma - radiotherapy; Adult; Aged; Aged, 80 and over; Analysis; Brachytherapy; Brachytherapy - methods; Cancer; Care and treatment; Chemotherapy; CT imaging; Diseases; Feasibility Studies; Female; Gastric cancer; Humans; Iodine-125 seed; Locoregional recurrence; Male; Middle Aged; Neoplasm Recurrence, Local - radiotherapy; Patient outcomes; Radiation therapy; Radioisotope brachytherapy; Radiotherapy, Image-Guided - methods; Relapse; Retrospective Studies; Seeds; Stomach cancer; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Stomach Neoplasms - radiotherapy; Surgery; Survival Analysis; Tomography, X-Ray Computed - methods; Treatment Outcome; China
• ISSN: 1748-717X; 1748-717X
• DOI: 10.1186/1748-717X-7-114

Locoregional recurrence is the typical pattern of recurrence in gastric cancer, and cannot be removed by surgery in most of the patients. We aimed to evaluate the feasibility and efficacy of computed tomography (CT)-guided brachytherapy for patients with locoregional recurrent gastric cancer. We reviewed the case histories of 28 patients with locoregional recurrent gastric cancer that were selected for CT- guided brachytherapy by a multidisciplinary team. The clinical data of the patients including patient characteristics, treatment parameters, short-term effects, and survival data were collected and analyzed. 15-75 125I seeds were implanted into each patient to produce a minimal peripheral dose (MPD) 100-160 Gy. Median day 0 dosimetry was significant for the following: V100 (the volume treated with the prescription dose) 95.8% (90.2-120.5%) and D90 (prescription dose received by at least 90% of the volume) 105.2% (98.0-124.6%) of prescription dose. No serious complications occurred during the study. Two months after brachytherapy, complete response, partial response and progressive disease were observed in 50.0%, 28.6% and 21.4% of patients, respectively. The median survival time was 22.0 ± 5.2 months, and the 1, 2,and 3-year survival rate was 89 ± 6%, 52 ± 10% and 11 ± 7%, respectively. A univariate analysis showed that the tumor size was a significant predictor of overall survival (P = 0.034). Patients with tumors <3 cm had relatively higher complete response rate (66.7%), compared to those with tumors >3 cm (30.8%). The PTV (planning target volume) smaller than 45 cm3 was significantly correlated with achieving complete tumor eradication in the treated region (P = 0.020). For selected patients with limited locoregional recurrent gastric cancer, CT-guided brachytherapy using 125I seeds implantation can provide a high local control rate, with minimal trauma.